Recent data suggest these engineered proteins can prevent the parasitic infection, but cost will ultimately determine if they are made available in low- and middle-income countries where they are needed most.

The COVID-19 experience, along with lingering manufacturing and delivery concerns, is prompting a harder look at the future of antibody-based treatment and prevention for infectious diseases.

Researchers at CROI discuss progress on the long road to developing an HIV vaccine.

Infections are at the highest levels since 1950 and fear of antimicrobial resistance is fueling new concerns over this old pathogen.

Nearly 150 years after the discovery of tuberculosis, researchers are still unraveling the fundamental biology and epidemiology of the germ and how best to defeat it.

The scientific implications of artificial intelligence loom large. One tangible application is designing better vaccines.

After more than three decades at the U.S. Food and Drug Administration, Gruber is continuing her legacy of changing the way vaccines are licensed and distributed.

Improving vaccine access topped the agenda at a major public health gathering in Berlin, where pandemic preparedness loomed large.

Exploring potential synergies between B- and T-cell HIV vaccine strategies is a priority for the field given results from recent trials.

Brittany Hartwell and her lab are exploring new ways to transport vaccine antigens across mucosal barriers to trigger more protective immune responses against many pathogens, including HIV.